title: Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life?
abstract: OBJECTIVE
  It is controversial whether pretreatment with a proton pump inhibitor (PPI) before Helicobacter pylori eradication treatment decreases the eradication rate. To determine the effects of pretreatment with lansoprazole alone, followed by an H. pylori eradication regimen (lansoprazole 30 mg, amoxicillin 750 mg and clarithromycin 200 mg twice daily for 1 week), on the eradication rate and quality of life (QoL) of the patient.
  
  
  METHODS
  Patients with H. pylori-positive peptic ulcer were randomly assigned to two groups. The patients received either lansoprazole (30 mg) once daily for 6-8 weeks before H. pylori eradication (group A), or eradication treatment and then lansoprazole (30 mg) for 6-8 weeks (group B). To assess the QoL of the patients, the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire was evaluated.
  
  
  RESULTS
  A total of 116 patients were enrolled. The cure rates were 78.9% in group A and 78.0% in group B. In both groups, GSRS analysis showed a significant improvement of the overall GSRS score at the assessment of eradication efficacy, compared to baseline; there was no difference between the groups.
  
  
  CONCLUSIONS
  With this H. pylori eradication regimen, there was no difference in the cure rates and QoL associated with PPI pretreatment.
authors.affiliation: Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Inoue
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okada
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Hori
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Kawahara
authors.forename: Seiji
authors.initials: S
authors.lastname: Kawano
authors.forename: Ryuta
authors.initials: R
authors.lastname: Takenaka
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Toyokawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Onishi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shiratori
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D064747:Lansoprazole; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D018709:Statistics, Nonparametric; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin